Larry Cohen and the business of beginning again

Larry Cohen has a wonderfully unglamorous name for the work of starting a business: “the calisthenics of small company formation.” It suggests repetition, effort, and a certain amount of counting. A venture can have an elegant idea and still need someone to work out who will pay for it. Cohen came to enjoy that part. Over a career that moved from the laboratory to operating roles and chief executive jobs, the mechanics of making a company became an occupation in their own right.

He now leads Health2047, the venture studio in Menlo Park, where he has served as chief executive since 2018. His earlier titles include research vice president, chief operating officer, president, and CEO. Read together, they describe a career spent moving among different kinds of responsibility. An experiment asks whether something works. A company adds questions about partners, financing, organization, and time. Cohen has spent years learning how to keep those questions in the same conversation.

The scientist acquires a second vocabulary

The formal education came first: a bachelor’s degree from Grinnell College, a doctorate in microbiology from the University of Illinois, and postdoctoral work in molecular biology at Dana-Farber and Harvard Medical School’s biochemistry department. His professional biography then traces a succession of operating roles at Somatix, Progenitor, Zyomyx, VIA Pharmaceuticals, and Kadmon Holdings. At Kadmon, his responsibilities eventually brought research and business development together in one executive title.

That sequence matters because a business-development conversation asks for a different explanation from a research discussion. A potential partner needs to understand what can be built together. An investor needs to understand what the money will make possible. A team needs to know which promises have become obligations. Cohen’s record includes responsibilities on both sides of those exchanges. The scientific training remained part of his background as the jobs became increasingly commercial.

In his account of the transition, the attraction was the variety: financing routes, public markets, intellectual property, and the negotiations that surround a young company. He describes becoming absorbed by entrepreneurship. The vocabulary multiplied. A person who once worked at the bench could find himself discussing an initial public offering, then a patent, then the next round of capital. It is an education with unusually expensive homework.

Nine new investors, one familiar problem

By December 2000, Cohen was chief operating officer of Zyomyx, a Hayward company developing laboratory tools. It had completed a $32.6 million Series D financing and brought nine new investors onto its shareholder list. Cohen explained that broadening that list was part of the intention. The company was preparing for its next financial stage, and the composition of its backing mattered alongside the total raised.

The figures he discussed were concrete: roughly $45 million in the bank and a monthly burn rate of about $1 million. These were company figures at that moment, rather than a measure of Cohen’s personal wealth. They also give a glimpse of what an operating executive has to hold in mind. Money in the bank buys time. Spending turns that time into work. Somewhere between the two sits a product that has to get closer to completion.

There is a useful tension in the episode. A financing announcement invites celebration; a burn rate invites arithmetic. Both belong to the same business. Cohen was speaking about the shape of the shareholder list while also describing the resources available to the company. The public picture included the cheque and the clock. For an executive, the clock is likely to be the more demanding companion.

A chip still needs a reader

In April 2001, Cohen was identified as Zyomyx’s CEO when the company announced an alliance with Axon Instruments. The partners planned to develop scanning products together. Zyomyx’s chip technology required instruments that could gather and analyze its signals. The partnership joined those parts of the product, a reminder that commercializing an invention often means finding the people who can build what surrounds it.

Cohen expected prototypes to go out that year. His description made room for something less polished than a finished product: the internal components could be present before the packaging was ready. It is a small detail with a recognizable startup character. A prototype must answer questions. Attractive packaging can wait its turn. Anyone who has watched a new product acquire its casing will recognize the order of business.

The alliance also looked beyond a single generation of equipment. The companies intended to evaluate different imaging approaches and develop successive scanning products. That placed the relationship on a longer timetable than one demonstration. An early device can establish that the pieces work together; later versions have to make the arrangement more useful. Cohen’s comments kept attention on that progression, from components to a system someone could actually use.

The appeal of a wider lens

By February 2003, Zyomyx had released its Protein Profiling Biochip System. The product combined a workstation, a scanner, analysis software, and biochips. It had taken nearly four years to develop. That interval puts some substance behind the earlier talk of prototypes and partnerships. A collection of promising parts had become an integrated product, with machinery and software sharing the job.

Cohen, then president and CEO, used a photographic comparison to explain the appeal of studying many proteins together: “a camera with a wide-angle lens.” The metaphor is revealing as communication. A reader did not have to understand the equipment to understand the wish for a fuller view. Cohen could describe a technical product through something familiar, giving the audience a way into the idea without requiring a laboratory vocabulary.

There is also a connection to the shape of his career. Research, operations, and business development each offer a different view of a company. Seeing more of the scene can complicate a decision, because more constraints become visible. It can also make a decision more useful. The metaphor belongs to a specific product explanation, but it is an apt way to read an executive history with so many changes of vantage point.

A new job, a larger table

VIA Pharmaceuticals followed. A 2004 employment agreement named Cohen president, chief executive, and treasurer, putting several kinds of accountability into the same appointment. He later worked at Kadmon before joining Health2047 in 2017. The studio was already established when he arrived. Its current biography dates his CEO tenure to 2018, distinguishing his arrival from the role he holds today.

In May 2018, Health2047 announced $27.2 million in follow-on financing from the American Medical Association. The organization intended to broaden its strategic partnerships and accelerate the creation of separate companies. Its executive roster also expanded, bringing together people with experience at Apple, Bain, Johnson & Johnson, IBM, and Fortress Investment Group. Cohen was operating inside a team whose previous workplaces represented quite different business cultures.

The shift gives the story a new scale. At Zyomyx, a partnership helped assemble a product system. At a venture studio, the work includes assembling companies themselves. A founder, an operator, an investor, and a potential partner may all describe the same opportunity differently. The practical question is whether their expectations can be made compatible long enough to build something. A strong idea still needs a workable arrangement among people.

The board has already heard the pitch

One of Cohen’s more economical pieces of advice concerns the boardroom. In April 2025, he urged founders to remember that investors had already committed to the venture. Board discussions should address difficult questions and progress against earlier goals. The implication is appealingly practical: once someone has invested, the meeting can move on to what happened after the presentation.

A founder’s polished account of the future has an obvious use in fundraising. The same account can occupy time that a board needs for decisions. Cohen’s advice gives that time a purpose. What has advanced? What is getting in the way? Which earlier objectives still make sense? A company has a better chance of benefiting from its directors if it brings them questions they can help answer.

He serves on boards within Health2047’s portfolio, so the advice comes from another seat in the same room. The founder is explaining the business; the director is trying to understand where attention is needed. Good communication makes those jobs fit together. A board meeting can become another performance of confidence, or it can become a useful working session. Cohen’s emphasis lands firmly on the work.

“It’s important to remember your investors are already bought in.”

Larry Cohen · April 2025

Back to the beginning, with more experience

The later record still shows Cohen in conversations about financing and company formation. In November 2025, Health2047 co-led Evidium’s $22 million Series A alongside WGG Partners. Interwoven Ventures and Mindset Ventures also participated. The announced uses of capital included product development, commercial expansion, and new hiring. It is another version of the questions visible at Zyomyx a quarter of a century earlier: what should money enable, and who needs to join?

The years have changed the setting and the scale of Cohen’s responsibilities. The recurring task remains easy to recognize. A company needs resources and a reason for those resources to arrive together. A new executive may inherit expertise in one part of that arrangement and have to learn the rest. Cohen’s career has repeatedly put him in that position, first as an operator, then as a chief executive, and now alongside founders.

There is something companionable about his choice of the word calisthenics. Starting again can sound grand when described from a distance. Up close, it involves another question about a partner, another conversation about capital, another explanation of what the product can do. Cohen’s professional life has made room for that repetition. The idea may be new. The responsibility is familiar, and there is still work to do before the company can stand on its own.